FDG-PET/CT: novel method for viability assessment of livers perfused ex vivo.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
pubmed:
21
3
2021
medline:
19
11
2021
entrez:
20
3
2021
Statut:
ppublish
Résumé
Ex vivo liver machine perfusion is a promising option to rescue marginal liver grafts mitigating the donated organ shortage. Recently, a novel liver perfusion machine that can keep injured liver grafts alive for 1 week ex vivo was developed and reported in Nature Biotechnology. However, liver viability assessment ex vivo is an unsolved issue and the value of 18F-fluorodeoxyglucose (FDG)-PET/CT for such purpose was explored. Discarded two human and six porcine liver grafts underwent FDG-PET/CT for viability assessment after 1 week of ex vivo perfusion. PET parameters [standardized uptake value (SUV)max, SUVmean, SUVpeak and total lesion glycolysis] were compared between hepatic lobes and between porcine and human livers. The prevalence of FDG-negative organ parts was recorded. The estimated effective radiation dose for PET/CT was calculated. All organs were viable with essentially homogeneous FDG uptake. Of note, viability was preserved in contact areas disclosing the absence of pressure necrosis. Four porcine and two human organs had small superficial FDG-negative areas confirmed as biopsy sites. Total lesion glycolysis was significantly higher in the right hepatic lobe (P = 0.012), while there was no significant difference of SUVmax, SUVmean and SUVpeak between hepatic lobes. There was no significant difference in FDG uptake parameters between porcine and human organs. The estimated effective radiation dose was 1.99 ± 1.67 mSv per organ. This study demonstrates the feasibility of FDG-PET/CT for viability assessment of ex vivo perfused liver grafts after 1 week.
Identifiants
pubmed: 33741853
doi: 10.1097/MNM.0000000000001399
pii: 00006231-202107000-00015
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
826-832Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Eshmuminov D, Becker D, Bautista Borrego L, Hefti M, Schuler MJ, Hagedorn C, et al. An integrated perfusion machine preserves injured human livers for 1 week. Nat Biotechnol. 2020; 38:189–198.
Eshmuminov D, Leoni F, Schneider MA, Becker D, Muller X, Hefti M, et al. Reply to “Ex situ normothermic machine perfusion of donor livers using a haemoglobin-based oxygen carrier: a viable alternative to red blood cells”. Transpl Int. 2018; 31:1283–1284.
Giwa S, Lewis JK, Alvarez L, Langer R, Roth AE, Church GM, et al. The promise of organ and tissue preservation to transform medicine. Nat Biotechnol. 2017; 35:530–542.
Muller X, Schlegel A, Kron P, Eshmuminov D, Würdinger M, Meierhofer D, et al. Novel real-time prediction of liver graft function during hypothermic oxygenated machine perfusion before liver transplantation. Ann Surg. 2019; 270:783–790.
Muller X, Schlegel A, Würdinger M, Wendt M, Kron P, Eshmuminov D, et al. Can hypothermic oxygenated perfusion (HOPE) rescue futile DCD liver grafts? HPB (Oxford). 2019; 21:1156–1165.
Vogel T, Brockmann JG, Quaglia A, Morovat A, Jassem W, Heaton ND, et al. The 24-hour normothermic machine perfusion of discarded human liver grafts. Liver Transpl. 2017; 23:207–220.
de Vries RJ, Tessier SN, Banik PD, Nagpal S, Cronin SEJ, Ozer S, et al. Supercooling extends preservation time of human livers. Nat Biotechnol. 2019; 37:1131–1136.
Bral M, Dajani K, Leon Izquierdo D, Bigam D, Kneteman N, Ceresa CDL, et al. A back-to-base experience of human normothermic ex situ liver perfusion: does the chill kill? Liver Transpl. 2019; 25:848–858.
Watson CJE, Kosmoliaptsis V, Pley C, Randle L, Fear C, Crick K, et al. Observations on the ex situ perfusion of livers for transplantation. Am J Transplant. 2018; 18:2005–2020.
Dutkowski P, Mueller M, Eshmuminov D, Bautista Borrego L, Becker D, Hefti M, et al. Reply to: lactate measurements in an integrated perfusion machine for human livers. Nat Biotechnol. 2020; 38:1263–1264.
Eshmuminov D, Becker D, Hefti ML, Mueller M, Hagedorn C, Dutkowski P, et al. Hyperoxia in portal vein causes enhanced vasoconstriction in arterial vascular bed. Sci Rep. 2020; 10:20966.
Becker D, Eshmuminov D, Keller R, Mueller M, Bautista Borrego L, Hagedorn C, et al. Automated insulin delivery - xontinuous blood glucose control during ex situ liver perfusion. IEEE Trans Biomed Eng. 2020. [Epub ahead of print]. doi: 10.1109/TBME.2020.3033663
doi: 10.1109/TBME.2020.3033663
Becker D, Hefti M, Schuler MJ, Borrego LB, Hagedorn C, Muller X, et al. Model Assisted analysis of the hepatic arterial buffer response during ex vivo porcine liver perfusion. IEEE Trans Biomed Eng. 2020; 67:667–678.
Eshmuminov D, Schuler MJ, Becker D, Bautista Borrego L, Mueller M, Hagedorn C, et al. Bile formation in long-term ex situ perfused livers. Surgery. 2021. [Epub ahead of print]. doi: 10.1016/j.surg.2020.11.042
doi: 10.1016/j.surg.2020.11.042
Eshmuminov D, Raptis DA, Linecker M, Wirsching A, Lesurtel M, Clavien PA. Meta-analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy. Br J Surg. 2016; 103:1768–1782.
Eshmuminov D, Tschuor C, Raptis DA, Boss A, Wurnig MC, Sergeant G, et al. Rapid liver volume increase induced by associating liver partition with portal vein ligation for staged hepatectomy (ALPPS): is it edema, steatosis, or true proliferation? Surgery. 2017; 161:1549–1552.
Kambakamba P, Stocker D, Reiner CS, Nguyen-Kim TD, Linecker M, Eshmuminov D, et al. Liver kinetic growth rate predicts postoperative liver failure after ALPPS. HPB (Oxford). 2016; 18:800–805.
Schneider PM, Eshmuminov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, et al. 18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC Cancer. 2018; 18:548.
Lehmann K, Eshmuminov D, Bauerfeind P, Gubler C, Veit-Haibach P, Weber A, et al. 18FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma. Eur J Surg Oncol. 2017; 43:196–202.
Li Y, Jiang L, Wang H, Cai H, Xiang Y, Li L. Effective radiation dose of 18f-fdg pet/ct: how much does diagnostic ct contribute? Radiat Prot Dosimetry. 2019; 187:183–190.
Icrp. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008; 38:1–197.
Valentin J; International Commission on Radiation Protection. Managing patient dose in multi-detector computed tomography(MDCT). ICRP Publication 102. Ann ICRP. 2007; 37:1–79, iii.
Zhang W, Fang C, Liu H, Chen Y. FDG PET/CT imaging of hepatocellular carcinoma with bile duct tumor thrombus. Clin Nucl Med. 2019; 44:130–132.
Perez PM, Flavell RR, Kelley RK, Umetsu S, Behr SC. Heterogeneous uptake of 18 F-FDG and 68 Ga-PSMA-11 in hepatocellular carcinoma. Clin Nucl Med. 2019; 44:e133–e135.
Zhong X, Dong A, Dong H, Wang Y. FDG PET/CT in 2 cases of hepatic pseudolymphoma. Clin Nucl Med. 2018; 43:e166–e169.
Zhang Y, Li B, Hou J, Yu H, Shi H. Hepatic epithelioid angiomyolipoma and 18 F-FDG PET/CT. Clin Nucl Med. 2018; 43:422–424.
Ma G, Li J, Xu B, Fu L. 18 F-FDG PET/CT in primary hepatic neuroendocrine tumors. Clin Nucl Med. 2018; 43:192–194.
Liu E, Wang S, Lai P, Lian Z, Wang S. “Hepatic superscan” in a patient with hepatosplenic alphabeta T-cell lymphoma: 18F-FDG PET/CT findings. Clin Nucl Med. 2018; 43:595–598.
Levin D, Hod N, Anconina R, Ezroh Kazap D, Shaco-Levy R, Lantsberg S. Peliosis hepatis simulating metastatic liver disease on FDG PET/CT. Clin Nucl Med. 2018; 43:e234–e236.
Derlin T, Hartung D, Hueper K. 18 F-FDG PET/CT for molecular imaging of hepatoblastoma in Beckwith-Wiedemann syndrome. Clin Nucl Med. 2018; 43:e164–e165.
Liu G, Xu H, Hu P, Tan H, Zhang Y, Yu H, et al. Kinetic metrics of (18)F-FDG in normal human organs identified by systematic dynamic total-body positron emission tomography. Eur J Nucl Med Mol Imaging. 2021. [Epub ahead of print]. doi: 10.1007/s00259-020-05124-y
doi: 10.1007/s00259-020-05124-y
Brix G, Ziegler SI, Bellemann ME, Doll J, Schosser R, Lucht R, et al. Quantification of [(18)F]FDG uptake in the normal liver using dynamic PET: impact and modeling of the dual hepatic blood supply. J Nucl Med. 2001; 42:1265–1273.
Messerli M, Kotasidis F, Ferraro DA, Kudura K, Treyer V, Trinckauf J, et al. Whole-body parametric [(18)F]-FDG PET/CT improves interpretation of a distant lesion as venous embolus in a lung cancer patient. Eur J Nucl Med Mol Imaging. 2021. [Epub ahead of print]. doi: 10.1007/s00259-020-05176-0
doi: 10.1007/s00259-020-05176-0
Aschenbach JR, Steglich K, Gäbel G, Honscha KU. Expression of mRNA for glucose transport proteins in jejunum, liver, kidney and skeletal muscle of pigs. J Physiol Biochem. 2009; 65:251–266.
Karim S, Adams DH, Lalor PF. Hepatic expression and cellular distribution of the glucose transporter family. World J Gastroenterol. 2012; 18:6771–6781.
Iozzo P, Geisler F, Oikonen V, Maki M, Takala T, Solin O, et al. Insulin stimulates liver glucose uptake in humans: an 18F-FDG PET study. J Nucl Med. 2003; 44:682–689.
Roy FN, Beaulieu S, Boucher L, Bourdeau I, Cohade C. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med. 2009; 50:178–183.
Puiman P, Stoll B. Animal models to study neonatal nutrition in humans. Curr Opin Clin Nutr Metab Care. 2008; 11:601–606.
Belakhlef S, Church C, Hays A, Fraser R, Lakhanpal S. Quantitative assessment of the influence of location, internal temperature, idle time, and normalization on the sensitivity of a mobile PET/CT scanner. J Nucl Med Technol. 2008; 36:147–150.
Li K, Mathews A, Wang Q, Wen J, O’Sullivan JA, Tai YC. Preliminary results from a portable PET probe system with fast image reconstruction. 2014 Ieee Nuclear Science Symposium and Medical Imaging Conference (Nss/Mic); 8–15 November 2014; Seattle. 2014.
Borra R, Lautamäki R, Parkkola R, Komu M, Sijens PE, Hällsten K, et al. Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus. Metabolism. 2008; 57:1445–1451.
Rijzewijk LJ, van der Meer RW, Lubberink M, Lamb HJ, Romijn JA, de Roos A, et al. Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism. Diabetes. 2010; 59:2747–2754.